BioCentury: Elicio vaccine targets oncogenic KRAS mutations

Elicio Therapeutics (Cambridge, Mass.) showed its ELI-002 vaccine generated immune responses against all common KRAS mutations, resulting in cytolytic activity against cells expressing the mutations. Data were presented at the Immuno-Oncology Summit in Boston. The vaccine contains seven peptides harboring mutations present in KRAS-driven cancers and modified with lymph node-targeting amphiphile groups. Elicio plans to begin Phase I/II trials of ELI-002 in pancreatic and colorectal cancers in 2020 (see “Elicio Raises $30M to Target Cancer Vaccines to the Lymph Nodes”).. FULL STORY»